Friday, April 29, 2011
Major pharmacology companies cutting back on psychtropic research
According to the podcast from Science, a few of the larger drug companies are doing large cut backs on CNS drugs (which includes meds for mental health) siting that they cost the most to develop, take the longest, and are the least likely to get FDA approval. This is fairly significant as there's a fairly limited amount of ways currently to treat mental health problems chemically, and their efficacy varies greatly between people and particular challenges. What remains to be seen is how the gap between need, and supports available will be filled, as many insurance companies seem to want to keep their panels closed, the public clinic's are running over capacity and many in need cannot afford private pay (one of the main reasons I like working for myself, so I can do sliding scale so I can see people with need if I have appointments times open) .